关于锂处方和监测的初级和中级医疗联合研究

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2024-01-01 DOI:10.1002/pnp.823

Seema Vekaria, Chetan Shah, Tim Gale, Cathy Geeson, Maxine Davis, Janet Weir, Promilla Singh

{"title":"关于锂处方和监测的初级和中级医疗联合研究","authors":"Seema Vekaria, Chetan Shah, Tim Gale, Cathy Geeson, Maxine Davis, Janet Weir, Promilla Singh","doi":"10.1002/pnp.823","DOIUrl":null,"url":null,"abstract":"Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Joint primary and secondary care study of lithium prescribing and monitoring\",\"authors\":\"Seema Vekaria, Chetan Shah, Tim Gale, Cathy Geeson, Maxine Davis, Janet Weir, Promilla Singh\",\"doi\":\"10.1002/pnp.823\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.\",\"PeriodicalId\":43913,\"journal\":{\"name\":\"Progress in Neurology and Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neurology and Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pnp.823\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.823","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

锂被授权用于治疗和预防躁狂症、双相情感障碍、复发性抑郁症和故意自残行为。尽管锂很有效，但其狭窄的治疗范围使其使用变得复杂。2009 年，美国国家患者安全机构发布了一份安全警示，强调了相关问题，并要求国家医疗服务系统各组织确保建立可靠的系统和监控。本文探讨了初级和中级医疗机构在锂的处方和监测方面是如何遵循指南的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Joint primary and secondary care study of lithium prescribing and monitoring

Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self‐harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.